・ Graduated from Shenyang Pharmaceutical University in 2008. After working in regulatory affairs and business development at EPS, Astellas, Asahi Kasei, dMed-Clinipac, and Redbud Medicine, he founded Global CR Med in 2023.
・ With 16 years of pharmaceutical industry experience, familiar with the regulatory and technical requirements for drug development and registration in China. Specialized in regulatory affairs and business development.
・ Involved in over 100 regulatory-related projects across therapeutic areas such as oncology, hematology, endocrinology, pain management, immunology, nephrology/urology, dermatology, inflammatory diseases, and ophthalmology.
・ Involved in the development of many imported products in China, including Enzalutamide Soft Capsules (XTANDI®), Gilteritibib (XOSPATA®) Tablets, Naftopidil (Flivas®) Tablets, Febuxostat Tablets (Feburic®), Loxoprofen Sodium Patches/Paps, Tacrolimus Capsules, Mirabegron Sustained-release Tablets, and Mizoribine Tablets, and played a leading role in some of the projects.
・ Obtained PMP (Certificate of Project Management professional), NPDP (Certificate of New Product Development Professional), and PRINCE2 (Projects IN Controlled Environments) qualifications.